Leerink Partnrs Predicts Editas Medicine Q3 Earnings

Editas Medicine, Inc. (NASDAQ:EDIT) – Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for Editas Medicine in a research note issued on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar anticipates that the company will earn ($0.14) per share for the quarter. The consensus estimate for Editas Medicine’s current full-year earnings is ($2.71) per share. Leerink Partnrs also issued estimates for Editas Medicine’s Q4 2025 earnings at ($0.14) EPS.

Editas Medicine (NASDAQ:EDIT) last issued its quarterly earnings data on Wednesday, March 5th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.16). The company had revenue of $30.60 million for the quarter, compared to analysts’ expectations of $37.17 million. Editas Medicine had a negative return on equity of 80.13% and a negative net margin of 340.96%. During the same quarter last year, the company earned ($0.23) earnings per share.

Editas Medicine Stock Up 1.2 %

Shares of Editas Medicine stock opened at $1.29 on Friday. Editas Medicine has a 52-week low of $0.91 and a 52-week high of $6.69. The firm’s 50 day moving average price is $1.46 and its 200-day moving average price is $1.90. The company has a market cap of $107.57 million, a P/E ratio of -0.50 and a beta of 2.16.

Hedge Funds Weigh In On Editas Medicine

A number of large investors have recently made changes to their positions in EDIT. Raymond James Financial Inc. acquired a new position in Editas Medicine during the 4th quarter valued at about $303,000. Barclays PLC raised its holdings in shares of Editas Medicine by 46.9% in the third quarter. Barclays PLC now owns 178,507 shares of the company’s stock worth $607,000 after buying an additional 56,986 shares during the last quarter. Monaco Asset Management SAM acquired a new stake in shares of Editas Medicine during the fourth quarter worth $1,359,000. Stifel Financial Corp grew its holdings in shares of Editas Medicine by 37.9% during the third quarter. Stifel Financial Corp now owns 624,876 shares of the company’s stock valued at $2,131,000 after buying an additional 171,656 shares during the last quarter. Finally, SG Americas Securities LLC increased its position in shares of Editas Medicine by 103.7% in the 4th quarter. SG Americas Securities LLC now owns 81,669 shares of the company’s stock valued at $104,000 after acquiring an additional 41,573 shares during the period. 71.90% of the stock is owned by institutional investors and hedge funds.

About Editas Medicine

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.